Thirty patients with primary cocaine dependence who had used cocaine within the past 24 hours and were being admitted to a detoxification ward were rated for signs and symptoms of cocaine abstinence and craving.
It has been proposed that dopamine (DA) depletion "may underlie dysphoric effects of cocaine abstinence, and cocaine urges" (Dackis and Gold 1985) . This hy pothesis led to the use of dopaminergic agonists such as bromocriptine, amantadine, or L-dihydroxyphenyl alanine (L-DOPA) to facilitate cocaine abstinence (Dac kis et al. 1987; Kostin et al. 1988; Tenant and Sagherian 1987; Cocores et al. 1989) .
In a prior open trial (Wolfsohn and Angrist 1990) , we assumed that DA depletion would be maximal in the earliest phase of cocaine abstinence and admin istered L-DOPA/carbidopa (250 mg/25 mg, respectively) to eight cocaine-dependent patients who were enter inga detoxibcation ward. Two doses were administered on the fIrst hospital day. On the next day, six of the eight patients spontaneously reported that they had slept unusually well; all eight said they felt less anx ious than after prior periods of cocaine discontinuation.
of the day of admission and after the final morning dose the next day. No significant differences in abstinence scores were found between the two treatment groups. The lack of drug-placebo differences appeared to be mainly due to rapid clearing of abstinence symptoms in the placebo treated patients. lNeuropsychopharmacology 9:49-53,
19931
The patients were not on the ward at the same time and the consistency of the effects reported seemed greater than might be expected if placebo effects alone were involved. These promising results suggested the need for replication under placebo-controlled conditions.
METHODS

Subjects
Thirty patients who were entering a detoxibcation ward for primary cocaine dependence enrolled in our study after giving informed consent to participate. Cocaine use within the last 24 hours was required for inclusion. One subject, however, was included who had used co caine 33 hours previously because he had prominent abstinence symptoms.
Subjects were excluded if they had been drinking heavily: had a positive morning admission breathalyzer test; acknowledged drinking eight cans of beer, three pints of wine, or one pint of distilled spirits daily; the admitting clinician felt that a chlordiazepoxide detoxi fIcation regimen was indicated. We chose these criteria rather than DSM III-R criteria for alcohol dependence because the latter emphasized inability to discontinue drinking, whereas the specrnc concern in this study was that alcohol withdrawal the fIrst morning in the hospi-tal would obscure cocaine abstinence symptoms. Lesser alcohol use and marijuana use were not exclusion criteria. Opiate-dependent subjects who required methadone detoxifIcation were also excluded. One sub ject who had been on a methadone maintenance pro gram for 10 years and was continuing maintenance was not excluded. Patients were also excluded if addicted to benzodiazepines or barbiturates or if they had medi cal conditions that would contraindicate L-DOPA ad ministration, such as glaucoma, melanoma, endoge nous psychotic disorders, cardiac arrhythmia, or any condition in which hypotension or vomiting would be potentially dangerous. Psychosis during cocaine intox ication was not cause for exclusion (Satel et a1. 1990; Brady et a1. 1991) .
Procedures
If willing to participate, subjects had an electrocardio graph and breathalyzer test. They were then inter viewed for a baseline rating of cocaine abstinence signs and symptoms (by RW). Immediately thereafter L-DOPA/carbidopa (100 mg/25 mg) or placebo was ad ministered (between 9 AM and 11 AM) . Active drug or placebo was repeated at 4 PM, 9 PM, and 8 AM the next day unless nausea or hypotension occurred. Repeated ratings were done (by both RW and BA) late the after noon of admission (between 5 PM and 6 PM) and late the next morning (between 11 AM and Noon). For these ratings the patient was interviewed by both investiga tors and a consensus reached for each item of the scale.
Assessment of Cocaine Abstinence
Because no standardized instrument for quantifying co caine abstinence exists, a scoring sheet was designed for this study. It assessed 1) the early abstinence pat tern of dysphoria, irritability, anxiety, agitation, and combined desire for sleep and insomnia generally re ferred to as the "crash" (Kramer et al. 1967; Siegel 1982; Gawin and Kleber 1986) ; 2) depression; 3) anergia; and 4) craving. For the hrst three clusters, individual items representing both subjective and objective assessments were scored on a four-point scale corresponding to not present (0), mild (1), moderate (2), and severe (3). For craving, a global subjective score with the same anchor points (0 to 3) was used. The scoring sheet used is shown in Appendix A.
Statistical Analyses
Rating scale data were analyzed using a two-factor anal ysis of variance design, in which placebo-active drug group (two levels) was a between subjects factor and treatment period (three levels) was a within subjects NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.1 factor. Chi-square and t-tests were used to determine if placebo and active treatment groups differed with reo spect to any of the demographic variables.
RESULTS
Two patients were dropped after enrollment, and their ratings were not used in the data analysis. This deci sion was made because of the emergence of conditions that overshadowed symptoms of cocaine abstinence: opiate withdrawal in one patient and major depression with suicidality in the second. These two patients had been randomized to placebo and active drug, respec tively. Thus the results presented are for two groups of 14 patients, who received either placebo or L-DOPA! carbidopa.
Clinical and demographic characteristics of the two patient groups did not differ. These are shown in Ta ble l.
Abstinence symptom scores were equivalent for the two treatment groups and showed a progressive de cline over 24 hours in both groups. The rate of decline was similar for the two groups. None of the posttreat ment ratings differed signifIcantly between patients who received L-DOPA/carbidopa and those who re ceived placebo. Combined subjective and objective (to tal) scores for "crash" phase measures, depression, and anergia and subjective ratings of cocaine craving are shown in Table 2 . There were no signifIcant differences between the L-DOPA and placebo groups by I-test for continuous variables or chi-square for dichotomous variables. * One placebo subject had 24 convictions. A I-test was inappropri· ate for this analysis. Mann-Whitney U = 87.0, P = .54. Analysis of variance showed no difference between placebo and active treatment groups for any given rating.
DISCUSSION
This placebo-controlled study failed to confrrm the resu l ts 1990). The possible reasons are as follows. There were diff erences in the dosage schedules. In the initial trial, patients received two doses of L-DOPA 250 mg/car bidopa 25 mg, that is, cumulative doses of 500 mg L-DOPA and 50 mg carbidopa in a day. The present study used four doses of L-DOPA 100 mg/carbidopa 25 mg, that is, cumulative doses of 400 mg L-DOPA and lOOmg carbidopa. A difference of only 100 mg L-DOPA seems an unlikely explanation of the different fIndings in the two trials, particularly because a higher dose of carbidopa was administered in the second study. An other reason is that patients (and raters) were "fooled" in the fIrst trial in that they wrongly attributed the rapid resolution of abstinence symptoms to the drug that was administered.
In this study, however, a similar rapid resolution of abstinence symptoms occurred in placebo-treated pa tients as in those who received active agent. This fInding corresponds rather closely to a recent study of cocaine abstinence (Satel et al. 1991) in which the authors con cluded "symptoms after inpatient cessation of uncom plicated cocaine addiction are relatively mild .... The fInd i ngs cal agents in the inpatient management of such pa tients."
The lack of a drug-placebo difference in this study could be interpreted as implying that either DA deple tion does not contribute to the symptoms of cocaine ab stinence or that the treatment used in this study did not aff ect the changes in DA system functioning that had occurred.
With respect to the frrst possibility, Satel et al. (1991) found only limited evidence for dysregulated dopaminergic function in their studies of plasma prolactin, growth hormone, and homovanillic acid during cocaine abstinence. On the other hand, preclinical and clinical data indicate some degree of dopaminergic dysregula tion after cocaine exposure. In preclinical studies, per sistent depletion of DA and its metabolites has been shown after a week of cocaine treatment (Wyatt et al. 1988) . Glucose metabolism in DA-reward regions has been shown to be reduced by cocaine treatment and this reduction was reversed by bromocriptine (Clow and Hammer 1991) . Similarly, cocaine self-administration has been shown to elevate thresholds for intracranial self-stimulation, a model of postcocaine anhedonia (Markou and Koob 1991) , and this effect is also reversed by bromocriptine (Markou and Koob 1992) . In clinical positron emission tomography studies, postsynaptic DA receptors have been shown to be diminished in co caine abusers, particularly early in abstinence (Volkow et al. 1990) .
The possibility that L-DOPA/carbidopa administra tion could not reverse changes in DA system function also cannot be dismissed lightly. Positron emission tomography studies with F-18-DOPA suggest dimin ished brain L-DOPA uptake after cocaine abuse (Bax ter et al. 1988) . Thus although administration of L-DOPA with decarboxylase inhibitors results in plasma L-DOPA levels many times greater than those which occur under physiologic conditions (Zurcher and Da Prada 1979; Da Prada 1984; Da Prada et al. 1987 ), brain uptake of L-DOPA may remain a limiting factor.
Finally, the design of this study, its fIndings and its limitations, need to be viewed in a larger context. A DA depletion hypothesis of cocaine addiction implies the possible therapeutic use of DA agonists. This study was designed to test whether L-DOPA/carbidopa could reverse cocaine abstinence signs and symptoms. We chose to study this question during the brief period when stimulant abstinence symptoms are most promi nent (Kramer et al. 1967; Siegel 1982; Gawin and Kle ber 1986; Satel et al. 1991) . The rapid clearing of indices of abstinence in our placebo-treated subjects precluded demonstrating a drug-placebo difference. However, this study cannot be considered a test of L-DOPA/car bidopa as a treatment for cocaine dependence, and it should be explicitly noted that the fIndings of this study in no way exclude a potential therapeutic role for L-DOPA or other DA agonists in cocaine addiction. A 24-hour inpatient trial is self-evidently quite different from an extended trial in outpatients in whom stress ful life events, social problems, psychiatric problems, and conditioned cues might interact with dopaminer gic dysregulation to increase relapse vulnerability (O'Brien et al. 1988) . Thus a defInitive trial of L-DOPA or any other therapeutic strategy as a treatment of co caine addiction must be done in outpatients over clini cally meaningful time periods.
